Skip to content

Study · Animal study (in vivo) · mouse · 2019

9 results

Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes.

He Z, Hu Y, Gui Z, Zhou Y, Nie T, Zhu J, Liu Z, Chen K, Liu L, Leong KW, Cao P, Chen Y, Mao HQ

Journal of controlled release : official journal of the Controlled Release Society17 Mar 2019Cited by 61 (Europe PMC)

PMID30894322 (opens in a new tab)DOI10.1016/j.jconrel.2019.03.014 (opens in a new tab)PepBankPUB-30894322
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, nanoparticle exendin‑4 produced an AUC 7.2-fold higher than free exendin‑4 injection.

    In plain wordsIn mice, nanoparticle exendin‑4 produced greater drug exposure than free exendin‑4 injection.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseExendin-4 AUC
    Study

    mousen: not reported in source

    Comparator
    free exendin-4 injection
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal injection in mice showed that exendin-4 released from the nanoparticles had an AUC 7.2-fold higher than the free exendin-4 injection.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, nanoparticle exendin‑4 normalized blood glucose within <12 h and maintained normal levels for 72 h.

    In plain wordsIn diabetic mice, nanoparticle exendin‑4 reduced blood glucose to normal and maintained it for 72 h.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucose normalization and maintenance
    Study

    mousen: not reported in source

    type II diabetes mouse model
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Efficacy study in a T2D mouse model showed that the optimized formulation achieved a rapid reduction of the blood glucose level to the normal range within <12 h and maintained the same level for 72 h following a single intraperitoneal dose.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, nanoparticle exendin‑4 maintained blood glucose below 15 mmol/L for 6 days.

    In plain wordsIn diabetic mice, nanoparticle exendin‑4 kept blood glucose below the stated therapeutic threshold for 6 days.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTherapeutic glucose threshold
    Study

    mousen: not reported in source

    type II diabetes mouse model
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The blood glucose level was maintained to below the therapeutic level (< 15 mmol/L) for 6 days, and the treatment led to reduced body weight with pathological and functional improvements in the kidney and liver.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, nanoparticle exendin‑4 reduced body weight.

    In plain wordsIn diabetic mice, nanoparticle exendin‑4 reduced body weight.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    mousen: not reported in source

    type II diabetes mouse model
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The blood glucose level was maintained to below the therapeutic level (< 15 mmol/L) for 6 days, and the treatment led to reduced body weight with pathological and functional improvements in the kidney and liver.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, nanoparticle exendin‑4 improved kidney pathology and function.

    In plain wordsIn diabetic mice, nanoparticle exendin‑4 improved kidney pathology and function.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedKidney pathology and function
    Study

    mousen: not reported in source

    type II diabetes mouse model
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The blood glucose level was maintained to below the therapeutic level (< 15 mmol/L) for 6 days, and the treatment led to reduced body weight with pathological and functional improvements in the kidney and liver.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, nanoparticle exendin‑4 improved liver pathology and function.

    In plain wordsIn diabetic mice, nanoparticle exendin‑4 improved liver pathology and function.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedLiver pathology and function
    Study

    mousen: not reported in source

    type II diabetes mouse model
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The blood glucose level was maintained to below the therapeutic level (< 15 mmol/L) for 6 days, and the treatment led to reduced body weight with pathological and functional improvements in the kidney and liver.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 07LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Activity measurement

    In lab tests, ternary nanoparticles achieved approximately complete exendin‑4 encapsulation.

    In plain wordsIn lab tests, nanoparticles encapsulated approximately all the exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEncapsulation efficiency
    Study

    n: not reported in source

    tannic acid/exendin-4/Fe nanoparticles
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Adapting our recently developed flash nanocomplexation (FNC) method, we formulated nanoparticles with high encapsulation efficiency (~ 100%) of exendin-4,

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 08LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Activity measurement

    In lab tests, ternary exendin‑4 nanoparticles had high payload capacity.

    In plain wordsIn lab tests, exendin‑4 nanoparticles had high payload capacity.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicablePayload capacity
    Study

    n: not reported in source

    tannic acid/exendin-4/Fe nanoparticles
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    high payload capacity, and high degrees of uniformity and stability because the rapid turbulent mixing facilitated a homogeneous distribution of all three components in the complexation process.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 09LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Activity measurement

    In lab tests, ternary exendin‑4 nanoparticles had high uniformity and stability from homogeneous component distribution.

    In plain wordsIn lab tests, exendin‑4 nanoparticles had high uniformity and stability.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableUniformity and stability
    Study

    n: not reported in source

    tannic acid/exendin-4/Fe nanoparticles
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    high payload capacity, and high degrees of uniformity and stability because the rapid turbulent mixing facilitated a homogeneous distribution of all three components in the complexation process.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.